<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33034015</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1708-0428</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>31</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Obesity surgery</Title>
          <ISOAbbreviation>Obes Surg</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Outcomes with Intra-gastric Balloon Therapy in BMI &lt; 35 Non-morbid Obesity: 10-Year Follow-Up Study of an RCT.</ArticleTitle>
        <Pagination>
          <StartPage>781</StartPage>
          <EndPage>786</EndPage>
          <MedlinePgn>781-786</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11695-020-04986-3</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE">Intra-gastric balloon (IGB) therapy is the most established endoscopic treatment of obesity, but there is a paucity of literature on long-term efficacy. This study aims to evaluate the short- and long-term weight loss efficacy of IGB.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS">Double-blinded RCT with 6-month IGB vs with sham endoscopy, in body mass index (BMI) 27-35 patients. Anthropometric, fasting glucose, and lipid profile measurement as early outcomes (up to 2 years) and 10-year follow-up. Primary outcomes were total body weight loss (kg) and BMI. Secondary outcomes were new-onset diabetes mellitus, other new comorbidities, and willingness for further intervention.</AbstractText>
          <AbstractText Label="RESULTS">Initial RCT recruited 99 patients (50 IGB vs 49 sibutramine group). Forty-nine patients (26 IGB vs 23 control group) participated in a 10-year review (follow-up rate of 51.6%). Total body weight loss at 6 (9.75 vs 7.48 kg, p = 0.03), 12 (6.52 vs 4.42 kg, p = 0.05), 18 (5.42 vs 3.57, p = 0.32), and 24 months (4.07 vs 2.93 kg, p = 0.56) favored the IGB group. Total weight loss (TWL) at 10 years (0.03 vs - 2.32 kg, p = 0.05) and %TWL (- 0.16 ± 12.8% vs - 2.84 ± 5.6%, p = 0.39) were not significantly different between groups. Follow-up BMI (30.97 ± 1.6 vs 30.38 ± 1.8 kg/m<sup>2</sup>, p = 1.00) was similar. At 10 years, new-onset diabetes mellitus, sleep apnoea, metabolic syndrome, and arthralgia were not significant (p &gt; 0.05). Twenty-three (81%) IGB group vs 13 (56%) control expressed a willingness for further intervention (p &lt; 0.01).</AbstractText>
          <AbstractText Label="CONCLUSION">IGB delivers weight loss to 2 years and is superior to control. However, new comorbidity development is not significantly different at 10 years. Patient that received IGB therapy were subsequently more willing for further bariatric metabolic intervention.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chan</LastName>
            <ForeName>Daniel L</ForeName>
            <Initials>DL</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Upper Gastrointestinal &amp; Metabolic Surgery, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, Western Sydney University, Sydney, New South Wales, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, The University of New South Wales, Sydney, New South Wales, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cruz</LastName>
            <ForeName>Josil R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Southern Philippines Medical Center, Davao City, Philippines.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mui</LastName>
            <ForeName>Wilfred L</ForeName>
            <Initials>WL</Initials>
            <AffiliationInfo>
              <Affiliation>Hong Kong Bariatric and Metabolic Institute, Hong Kong, Hong Kong.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wong</LastName>
            <ForeName>Simon K H</ForeName>
            <Initials>SKH</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Upper Gastrointestinal &amp; Metabolic Surgery, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ng</LastName>
            <ForeName>Enders K W</ForeName>
            <Initials>EKW</Initials>
            <Identifier Source="ORCID">0000-0001-7219-5810</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Upper Gastrointestinal &amp; Metabolic Surgery, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong. endersng@surgery.cuhk.edu.hk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Obes Surg</MedlineTA>
        <NlmUniqueID>9106714</NlmUniqueID>
        <ISSNLinking>0960-8923</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015905" MajorTopicYN="Y">Gastric Balloon</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009767" MajorTopicYN="Y">Obesity, Morbid</DescriptorName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015431" MajorTopicYN="N">Weight Loss</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Bariatrics</Keyword>
        <Keyword MajorTopicYN="Y">Endoscopy</Keyword>
        <Keyword MajorTopicYN="Y">Gastric balloon</Keyword>
        <Keyword MajorTopicYN="Y">Obesity</Keyword>
        <Keyword MajorTopicYN="Y">Randomized controlled trial</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>9</Day>
          <Hour>5</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33034015</ArticleId>
        <ArticleId IdType="doi">10.1007/s11695-020-04986-3</ArticleId>
        <ArticleId IdType="pii">10.1007/s11695-020-04986-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.metabol.2018.09.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ko GT, Wu MM, Tang J, et al. Body mass index profile in Hong Kong Chinese adults. Ann Acad Med Singap. 2001;30(4):393–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11503547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collaboration APCS. The burden of overweight and obesity in the Asia-Pacific region. Obes Rev. 2007;8(3):191–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1467-789X.2006.00292.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2017.06.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Consultation WE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(03)15268-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kasama K, Mui W, Lee WJ, et al. IFSO-APC consensus statements 2011. Obes Surg. 2012;22(5):677–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11695-012-0610-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg. 2014;24(3):437–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11695-013-1160-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neylan CJ, Dempsey DT, Tewksbury CM, et al. Endoscopic treatments of obesity: a comprehensive review. Surg Obes Relat Dis. 2016;12(5):1108–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.soard.2016.02.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nieben OG, Harboe H. Intragastric balloon as an artificial bezoar for treatment of obesity. Lancet. 1982;1(8265):198–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(82)90762-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gore N, Ravindran P, Chan DL, et al. Pancreatitis from intra-gastric balloon insertion: case report and literature review. Int J Surg Case Rep. 2018;45:79–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijscr.2018.03.016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahman AA, Loi K. Gastric perforation as a complication of intragastric balloon. Surg Obes Relat Dis. 2018;14(5):719–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.soard.2018.01.019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425–38.e5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gie.2015.03.1964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saber AA, Shoar S, Almadani MW, et al. Efficacy of first-time intragastric balloon in weight loss: a systematic review and meta-analysis of randomized controlled trials. Obes Surg. 2017;27(2):277–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11695-016-2296-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng EK, Mui WL, Tsung BY, et al. 424 A prospective, randomized, double-blind, controlled trial on efficacy of weight reduction of endoscopic intragastric balloon versus oral sibutramine in patients with non-morbid obesity. Gastroenterology. 2009;136(5):A–73.</Citation>
        </Reference>
        <Reference>
          <Citation>James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1003114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung BM. Drug treatment for obesity in the post-sibutramine era. Drug Saf. 2011;34(8):641–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/11592040-000000000-00000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Association WM. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. Jama. 2013;310(20):2191–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Therapy AATFoEB. A pathway to endoscopic bariatric therapies. Surg Obes Relat Dis. 2011;7(6):672–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.soard.2011.09.008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neto MG, Silva LB, Grecco E, et al. Brazilian intragastric balloon consensus statement (BIBC): practical guidelines based on experience of over 40,000 cases. Surg Obes Relat Dis. 2018;14(2):151–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.soard.2017.09.528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tate CM, Geliebter A. Intragastric balloon treatment for obesity: review of recent studies. Adv Ther. 2017;34(8):1859–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12325-017-0562-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kyle TK, Dhurandhar EJ, Allison DB. Regarding obesity as a disease: evolving policies and their implications. Endocrinol Metab Clin N Am. 2016;45(3):511–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ecl.2016.04.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brethauer SA, Kothari S, Sudan R, et al. Systematic review on reoperative bariatric surgery: American Society for Metabolic and Bariatric Surgery Revision Task Force. Surg Obes Relat Dis. 2014;10(5):952–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.soard.2014.02.014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotzampassi K, Grosomanidis V, Papakostas P, et al. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg. 2012;22(6):896–903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11695-012-0607-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfredo G, Roberta M, Massimiliano C, et al. Long-term multiple intragastric balloon treatment--a new strategy to treat morbid obese patients refusing surgery: prospective 6-year follow-up study. Surg Obes Relat Dis. 2014;10(2):307–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.soard.2013.10.013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dumonceau JM, Francois E, Hittelet A, et al. Single vs repeated treatment with the intragastric balloon: a 5-year weight loss study. Obes Surg. 2010;20(6):692–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11695-010-0127-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Genco A, Lorenzo M, Baglio G, et al. Does the intragastric balloon have a predictive role in subsequent LAP-BAND((R)) surgery? Italian multicenter study results at 5-year follow-up. Surg Obes Relat Dis. 2014;10(3):474–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.soard.2013.10.021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leeman MF, Ward C, Duxbury M, et al. The intra-gastric balloon for pre-operative weight loss in bariatric surgery: is it worthwhile? Obes Surg. 2013;23(8):1262–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11695-013-0896-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ball W, Raza SS, Loy J, et al. Effectiveness of intra-gastric balloon as a bridge to definitive surgery in the super obese. Obes Surg. 2019;29(6):1932–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11695-019-03794-8</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
